SEARCH

SEARCH BY CITATION

References

  • Arcaini, L., Lazzarino, M., Colombo, N., Burcheri, S., Boveri, E., Paulli, M., Morra, E., Gambacorta, M., Cortelazzo, S., Tucci, A., Ungari, M., Ambrosetti, A., Menestrina, F., Orsucci, L., Novero, D., Pulsoni, A., Frezzato, M., Gaidano, G., Vallisa, D., Minardi, V., Tripodo, C., Callea, V., Baldini, L., Merli, F., Federico, M., Franco, V. & Iannitto, E. (2006) Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood, 107, 46434649.
  • Berger, F., Felman, P., Thieblemont, C., Pradier, T., Baseggio, L., Bryon, P.-A., Salles, G., Callet-Bauchu, E. & Coiffier, B. (2000) Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood, 95, 19501956.
  • Bolam, S., Orchard, J. & Oscier, D. (1997) Fludarabine is effective in the treatment of splenic lymphoma with villous lymphocytes. British Journal of Haematology, 99, 158161.
  • Byrd, J.C., Peterson, B.L., Morrison, V.A., Park, K., Jacobsen, R., Hoke, E., Vardiman, J.W., Rai, K., Schiffer, C.A. & Larson, R.A. (2003) Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood, 101, 614.
  • Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. & Canellos, G.P. (1999a) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphoma. Journal of Clinical Oncology, 17, 12441253.
  • Cheson, B.D., Vena, D.A., Barrett, J. & Freidlin, B. (1999b) Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. Journal of Clinical Oncology, 17, 24542460.
  • Conconi, A., Martinelli, G., Thieblemont, C., Ferreri, A.J.M., Devizzi, L., Peccatori, F., Ponzoni, M., Pedrinis, E., Dell’Oro, S., Pruneri, G., Filipazzi, V., Dietrich, P.-Y., Gianni, A.M., Coiffier, B., Cavalli, F. & Zucca, E. (2003) Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood, 102, 27412745.
  • Czuczman, M.S., Koryzna, A., Mohr, A., Stewart, C., Donohue, K., Blumenson, L., Bernstein, Z.P., McCarthy, P., Alam, A., Hernandez-Ilizaliturri, F., Skipper, M., Brown, K., Chanan-Khan, A., Klippenstein, D., Loud, P., Rock, M.K., Benyunes, M., Grillo-Lopez, A. & Bernstein, S.H. (2005) Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. Journal of Clinical Oncology, 23, 694704.
  • Fisher, R.I., Dahlberg, S., Nathwani, B.N., Banks, P.M., Miller, T.P. & Grogan, T.M. (1995) A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B cell subcategories): a Southwest Oncology Group Study. Blood, 85, 10751082.
  • Fisher, R.I., LeBlanc, M., Press, O.W., Maloney, D.G., Unger, J.M. & Miller, T.P. (2005) New treatment options have changed the survival of patients with follicular lymphoma. Journal of Clinical Oncology, 23, 84478452.
  • Hammel, P., Haioun, C., Chaumette, M., Gaulard, P., Divine, M., Reyes, F. & Delchier, J. (1995) Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. Journal of Clinical Oncology, 13, 25242529.
  • Harris, N.L., Jaffe, E.S., Stein, H., Banks, P.M., Chan, J.K., Cleary, M.L., Delsol, G., De Wolf-Peeters, C., Falini, B. & Gatter, K.C. (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood, 84, 13611392.
  • Jaeger, G., Neumeister, P., Brezinschek, R., Hinterleitner, T., Fiebiger, W., Penz, M., Neumann, H.J., Mlineritsch, B., DeSantis, M., Quehenberger, F., Chott, A., Beham-Schmid, C., Hoefler, G., Linkesch, W. & Raderer, M. (2002) Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study. Journal of Clinical Oncology, 20, 38723877.
  • Kalpadakis, C., Pangalis, G.A., Dimopoulou, M.N., Vassilakopoulos, T.P., Kyrtsonis, M.C., Korkolopoulou, P., Kontopidou, F.N., Siakantaris, M.P., Dimitriadou, E.M., Kokoris, S.I., Tsaftaridis, P., Plata, E. & Angelopoulou, M.K. (2007) Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematologic Oncology, 25, 127131.
  • Kaplan, E. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457481.
  • Leleu, X., Soumerai, J., Roccaro, A., Hatjiharissi, E., Hunter, Z.R., Manning, R., Ciccarelli, B.T., Sacco, A., Ioakimidis, L., Adamia, S., Moreau, A.S., Patterson, C.J., Ghobrial, I.M. & Treon, S.P. (2009) Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs. Journal of Clinical Oncology, 27, 250255.
  • Mantel, N. (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemotherapy Reports, 50, 163170.
  • Marcus, R., Imrie, K., Belch, A., Cunningham, D., Flores, E., Catalano, J., Solal-Celigny, P., Offner, F., Walewski, J., Raposo, J., Jack, A. & Smith, P. (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood, 105, 14171423.
  • Matutes, E., Oscier, D., Montalban, C., Berger, F., Callet-Bauchu, E., Dogan, A., Felman, P., Franco, V., Iannitto, E., Mollejo, M., Papadaki, T., Remstein, E.D., Salar, A., Sole, F., Stamatopoulos, K., Thieblemont, C., Traverse-Glehen, A., Wotherspoon, A., Coiffier, B. & Piris, M.A. (2008) Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia, 22, 487495.
  • McLaughlin, P., Estey, E., Glassman, A., Romaguera, J., Samaniego, F., Ayala, A., Hayes, K., Maddox, A.M., Preti, H.A. & Hagemeister, F.B. (2005) Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. Blood, 105, 45734575.
  • Melo, J.V., Hegde, U., Parreira, A., Thompson, I., Lampert, I.A. & Catovsky, D. (1987) Splenic B-cell lymphoma with circulating villous lymphocytes: differential diagnosis of B-cell leukemias with large spleens. Journal of Clinical Pathology, 40, 642651.
  • Morrison, V.A., Rai, K.R., Peterson, B.L., Kolitz, J.E., Elias, L., Appelbaum, F.R., Hines, J.D., Shepherd, L., Larson, R.A. & Schiffer, C.A. (2002) Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, Cancer and Leukemia Group B 9011. Journal of Clinical Oncology, 20, 38783884.
  • Mulligan, S.P., Matutes, E., Dearden, C. & Catovsky, D. (1991) Splenic lymphoma with villous lymphocytes: natural history and response to therapy in 50 cases. British Journal of Haematology, 78, 206209.
  • Nathwani, B.N., Drachenberg, M.R., Hernandez, A.M., Levine, A.M. & Sheibani, K. (1999) Nodal monocytoid B-cell lymphoma (nodal marginal-zone B-cell lymphoma). Seminars in Hematology, 36, 128138.
  • Van Oers, M.H., Klasa, R., Marcus, R.E., Wolf, M., Kimby, E., Gascoyne, R.D., Jack, A., Van’t Veer, M., Vranovsky, A., Holte, H., Van Glabbeke, M., Teodorovic, I., Rozewicz, C. & Hagenbeek, A. (2006) Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood, 108, 32953301.
  • Parry-Jones, N., Matutes, E., Gruszka-Westwood, A.M., Swansbury, G.J., Wotherspoon, A.C. & Catovsky, D. (2003) Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients. British Journal of Haematology, 120, 759764.
  • Savage, D.G., Cohen, N.S., Hesdorffer, C.S., Heitjan, D., Oster, M.W., Garrett, T.J., Bar, M., Del Prete, S., March, R., Lonberg, M., Talbot, S., Mears, G., Flamm, M., Taub, R.N. & Nichols, G. (2003) Combined fludarabine and rituximab for low-grade lymphoma and chronic lymphocytic leukemia. Leukemia and Lymphoma, 44, 477481.
  • Schulz, H., Klein, S.K., Rehwald, U., Reiser, M., Hinke, A., Knauf, W.-U., Aulitzky, W.-E., Hensel, M., Herold, M., Huhn, D., Hallek, M., Diehl, V., Engert, A., on behalf of the German CLL Study Group. (2002) Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood, 100, 31153120.
  • Sheibani, K., Sohn, C., Burke, J.S., Winberg, C.D., Wu, A.M. & Rappaport, H. (1986) Monocytoid B cell lymphoma: a novel B-cell neoplasm. American Journal of Pathology, 124, 310318.
  • Tam, C.S., Seymour, J.F., Prince, H.M., Kenealy, M., Wolf, M., Januszewicz, E.H. & Westerman, D. (2006) Treatment-related myelodysplasia following fludarabine combination chemotherapy. Haematologica, 91, 15461550.
  • Thieblemont, C., Bastion, Y., Berger, F., Rieux, C., Salles, G., Dumontet, C., Felman, P. & Coiffier, B. (1997) Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients. Journal of Clinical Oncology, 15, 16241630.
  • Thieblemont, C., Berger, F., Dumontet, C., Moullet, I., Bouafia, F., Felman, P., Salles, G. & Coiffier, B. (2000) Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood, 95, 802806.
  • Treon, S.P., Branagan, A.R., Ioakimidis, L., Soumerai, J.D., Patterson, C.J., Turnbull, B., Wasi, P., Emmanouilides, C., Frankel, S.R., Lister, A., Morel, P., Matous, J., Gregory, S.A. & Kimby, E. (2008) Long term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia. Blood, doi: DOI: 10.1182/blood-2008-09-177329
  • Troussard, X., Valensi, F., Duchayne, E., Garand, R., Felman, P., Tulliez, M., Henry-Amar, M., Bryon, P.A., Flandrin, G. & le Groupe Francaise d’Hematologie Cellulaire. (1996) Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. British Journal of Haematology, 93, 731736.
  • Tsimberidou, A.M., Catovsky, D., Schlette, E., O’Brien, S., Wierda, W.G., Kantarjian, H., Garcia-Manero, G., Wen, S., Do, K.A., Lerner, S. & Keating, M.J. (2006) Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer, 107, 125135.
  • Yasukawa, M., Yamauchi, H., Azuma, T., Takada, K., Ishimura, M. & Fujita, S. (2002) Dramatic efficacy of fludarabine in the treatment of an aggressive case of splenic lymphoma with villous lymphocytes. European Journal of Hematology, 69, 112114.